The DOI matches its Crossref record; the references it cites are not checked yet.
Current treatment options for Alzheimer’s disease and Parkinson’s disease dementia
Open accessAbstract
Alzheimer's disease (AD) and Parkinson's disease (PD) are the two most common neurodegenerative disorders encountered in clinical practice. Whilst dementia has long been synonymous with AD, it is becoming more widely accepted as part of the clinical spectrum in PD (PDD). Neuropsychiatric complications, including psychosis, mood and anxiety disorders, and sleep disorders also frequently co-exist with cognitive dysfunctions in AD and PDD patients. The incidence of such symptoms is often a significant source of disability, and may aggravate pre-existing cognitive deficits. Management of AD and PDD involves both pharmacological and non-pharmacological measures. Although research on pharmacological therapies for AD and PDD has so far had some success in terms of developing symptomatic treatments, the benefits are often marginal and non-sustained. These shortcomings have led to the investigation of non-pharmacological and novel treatments for both AD and PD. Furthermore, in light of the diverse constellation of other neuropsychiatric, physical, and behavioural symptoms that often occur in AD and PD, consideration needs to be given to the potential side effects of pharmacological treatments where improving one symptom may lead to the worsening of another, rendering the clinical management of these patients challenging. Therefore, the present article will critically review the evidence for both pharmacological and non-pharmacological treatments for cognitive impairment in AD and PD patients. Treatment options for other concomitant neuropsychiatric and behavioural symptoms, as well as novel treatment strategies will also be discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This therapeutic impasse extends beyond AD to other major cognitive disorders, including LBD (Agarwal et al., 2024), FTD (Magrath Guimet et al., 2022), and PDD (Szeto and Lewis, 2016), for which no disease-modifying therapies exist.”
From Multimodal neuroimaging and AI integration in cognitive disorders: advances, challenges, and future directions for precision medicine (2026) · cites this paper as Szeto and Lewis, 2016
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 155 · Cited by 198
Metadata
- Authors
- Y.Y. Szeto, J., & J.G. Lewis, S.
- Venue
- Current Neuropharmacology
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2016-04-08
- Volume
- 14
- Issue
- 4
- Pages
- 326-338
- ISSN
- 1570-159X (ISSN-L)
- PMC
- PMC4876589
- OpenAlex
- W2191458963
- Cited by
- 198
- References
- 155
- Citations by year
- 2026: 20 · 2025: 12 · 2024: 18 · 2023: 22 · 2022: 34 · 2021: 28 · 2020: 21 · 2019: 18 · 2018: 15 · 2017: 8 · 2016: 2
- FWCI
- 12.73
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc
- Locations
- Current Neuropharmacology (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- Alzheimer's disease, Parkinson's disease dementia, dementia, cognitive impairment, neuropsychiatric symptoms, psychosis, mood disorders, anxiety disorders, sleep disorders, pharmacotherapy, non-pharmacological treatment, new drugs, adverse drug reactions
- MeSH terms
- Rivastigmine, Donepezil, Alzheimer Disease, Animals, Antiparkinson Agents, Cholinesterase Inhibitors, Dementia, Exercise Therapy, Galantamine, Humans, Indans, Memantine, Parkinson Disease, Piperidines, Sleep Wake Disorders, Cognitive Behavioral Therapy, Treatment Outcome, Excitatory Amino Acid Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Current treatment options for Alzheimer’s disease and Parkinson’s disease dementia. https://app.cochat.ai/papers/10.2174/1570159x14666151208112754
- The paper
- Y.Y. Szeto, J., & J.G. Lewis, S. (2016). Current treatment options for Alzheimer’s disease and Parkinson’s disease dementia. Current Neuropharmacology. https://doi.org/10.2174/1570159x14666151208112754
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.